Denmark

Denmark regulates pharmaceutical products through the Danish Medicines Agency — Lægemiddelstyrelsen (DKMA), an EU member authority operating under the Medicines Act (Lægemiddelloven, Bekendtgørelse af lov om lægemidler) and fully aligned with EU pharmaceutical legislation. DKMA is a voting member of EMA's scientific committees (CHMP, PRAC, CAT, COMP, PDCO, HMPC) and CMDh, a founding PIC/S member, and a frequent Rapporteur — punching above its weight by volume per capita, particularly for biologics, diabetes, oncology and rare diseases (reflecting Denmark's strong domestic R&D base anchored by Novo Nordisk, Lundbeck, LEO Pharma, Genmab and Bavarian Nordic). EMA Centralised Procedure authorisations are directly valid in Denmark via Commission Implementing Decision; DCP, MRP and national procedures are handled by DKMA. The dossier follows EU eCTD; English is the working language for assessment, with Danish required for SmPC (Produktresumé), PIL (Indlægsseddel) and labelling. Denmark is part of the EU Falsified Medicines framework via the Danish Medicines Verification Organisation (DMVO) and applies EU GMP/GDP via PIC/S. Public-sector access splits between outpatient prescription medicines reimbursed under the general medicines reimbursement scheme (Medicintilskud) administered by DKMA on the advice of the Reimbursement Committee (Medicintilskudsnævnet), and hospital medicines funded by the five regions (Regioner) coordinated through the Danish Medicines Council — Medicinrådet — which issues national recommendations on new hospital medicines and treatment guidelines. Hospital procurement is centralised through Amgros I/S, the regions' joint procurement organisation, which negotiates confidential prices on behalf of all five regions. Denmark applies international reference pricing for outpatient medicines (against the nine other EEA countries with comparable price levels).